BRAF and neoplasm: Using a customized targeted NGS library kit (SureSelect QXT, Agilent Technologies, USA), Yao et al [38] investigated KRAS/NRAF/BRAF mutations in plasma and tumor samples of mCRC patients, and concordance rate of KRAS was 81.25% in 64 patients, with sensitivity of 66.7% and specificity of 90.0%.